TD Waterhouse Canada Inc. Purchases 307 Shares of IDEXX Laboratories, Inc. $IDXX

TD Waterhouse Canada Inc. raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 249.6% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 430 shares of the company’s stock after acquiring an additional 307 shares during the period. TD Waterhouse Canada Inc.’s holdings in IDEXX Laboratories were worth $233,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Opal Wealth Advisors LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter worth about $29,000. Ameritas Advisory Services LLC bought a new position in IDEXX Laboratories during the second quarter worth about $36,000. WPG Advisers LLC purchased a new position in shares of IDEXX Laboratories in the first quarter worth about $37,000. Bank of Jackson Hole Trust raised its position in shares of IDEXX Laboratories by 328.6% in the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock valued at $39,000 after purchasing an additional 69 shares during the period. Finally, NewSquare Capital LLC raised its position in shares of IDEXX Laboratories by 87.5% in the second quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock valued at $40,000 after purchasing an additional 35 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of several analyst reports. Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Weiss Ratings restated a “hold (c+)” rating on shares of IDEXX Laboratories in a research report on Wednesday, November 19th. BTIG Research raised their price target on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Piper Sandler reiterated a “neutral” rating and set a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Finally, JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $730.50.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Up 3.6%

IDEXX Laboratories stock opened at $752.14 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $759.33. The stock has a market cap of $60.06 billion, a P/E ratio of 62.63, a PEG ratio of 4.06 and a beta of 1.62. The firm’s fifty day moving average price is $658.28 and its 200-day moving average price is $599.27.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.08. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the company earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.